A Phase 2 interventional study of Ramucirumab and Placebo in Non-small Cell Lung Cancer Metastatic, sponsored by Eli Lilly and Company. Completed at 15 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-30.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is the only one that started in 2012, is one of 14 in phase 2, and was the 4th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
SWOG Cancer Research Network · Sites in United States
Ages 18 min+
By country, each count listing its studies:
Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 3
First in 2009; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 197 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 24 interventional studies. Of the 14 that completed or were terminated, 13 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 24 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 40th largest by enrollment of the 139 interventional ones that give a count, is one of 5 that started in 2012, is one of 73 in phase 2, and was the 95th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
2 of the studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT03909334Xiuning LeStudy of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of ramucirumab in combination with docetaxel in participants with Stage IV non-small cell lung cancer who have had disease progression during or after one prior first-line platinum-based chemotherapy with or without maintenance therapy for advanced/metastatic disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
Drug: Ramucirumab · Drug: Docetaxel
Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
Drug: Placebo · Drug: Docetaxel
Administered IV
Also known as: LY 3009806, IMC-1121B, Cyramza®
Administered IV
Administered IV
Progression-Free Survival (PFS)
PFS was defined as the time from baseline until measured progressive disease (PD) or death from any cause, whichever is first. According to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD, who were alive at the end of the follow-up period (or lost to follow-up), were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.
Time frame: Baseline to Measured Progressive Disease or Death from Any Cause (Up to 21 Months)
Overall Survival (OS)
OS was defined as time from baseline to the date of death from any cause. Participants who were alive at the end of the follow-up period (or lost to follow-up) were censored on the last date the participant was known to be alive.
Time frame: Baseline to Death from Any Cause (Up to 28 Months)
Percentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)]
Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \[ULN\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. The percentage of participants who achieved an objective response equals (number of participants with CR or PR)/(number of participants assessed)\*100.
Time frame: Baseline to Measured Progressive Disease or Participant Stops Study (Up to 97 Weeks)
Percentage of Participants Who Achieved Best Overall Disease Response of CR, PR or Stable Disease (SD) [Disease Control Rate (DCR)]
Participants achieved disease control if they had a best overall response of PR, CR or SD. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \[ULN\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started. The percentage of participants who achieved disease control equals (number of participants with CR, PR, or SD)/(number of participants assessed)\*100.
Time frame: Baseline to Measured Progressive Disease or Participant Stopped Study (Up to 97 Weeks)
Change From Baseline in European Quality of Life Questionnaire - 5 Dimension (EQ-5D) Index Score
The EQ-5D is a quality-of-life instrument which allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a scale from 1 to 3 (no problem, some problems, and extreme problems, respectively). These combinations of attributes were converted into a weighted Health State Index score according to a United Kingdom population-based algorithm; the possible values for the Health State Index score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).
Time frame: Baseline, Day 21 Each Cycle (Cycle = 21 Days) and 30-Day Follow Up (Up to 97 Weeks)
Change From Baseline in Lung Cancer Symptom Scale (LCSS)
The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant responses to each item were measured using a visual analog scale (VAS) from 0 (best outcome) to 100 (worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom-specific items in the LCSS. The Total LCSS was the mean of all 9 LCSS items. Maximum improvement in LCSS scores, ASBI, and Total LCSS score was the largest decrease from baseline for each variable, which was the smallest (most negative or smallest positive) non-missing value among all change from baseline values for each variable.
Time frame: Baseline to Measured Progressive Disease or Participant Stopped Study (up to 97 weeks)
| Milestone | Ramucirumab Plus Docetaxel | Placebo Plus Docetaxel |
|---|---|---|
| Started | 98 | 99 |
| Received at least one dose of study drug | 94 | 98 |
| Completed | 89 | 95 |
| Not completed | 9 | 4 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Sponsor decision | 1 | 0 |
PFS was defined as the time from baseline until measured progressive disease (PD) or death from any cause, whichever is first. According to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD, who were alive at the end of the follow-up period (or lost to follow-up), were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.
| Months | Ramucirumab + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Progression-Free Survival (PFS) | 5.22 (3.52 to 6.97) | 4.21 (2.83 to 5.62) |
OS was defined as time from baseline to the date of death from any cause. Participants who were alive at the end of the follow-up period (or lost to follow-up) were censored on the last date the participant was known to be alive.
| Months | Ramucirumab + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Overall Survival (OS) | 15.15 (12.45 to 26.55) | 14.65 (11.93 to 24.44) |
Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \[ULN\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. The percentage of participants who achieved an objective response equals (number of participants with CR or PR)/(number of participants assessed)\*100.
| Percentage of Participants | Ramucirumab + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Percentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)] | 28.9 (19.1 to 40.5) | 18.5 (10.8 to 28.7) |
Participants achieved disease control if they had a best overall response of PR, CR or SD. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \[ULN\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started. The percentage of participants who achieved disease control equals (number of participants with CR, PR, or SD)/(number of participants assessed)\*100.
| Percentage of Participants | Ramucirumab + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Percentage of Participants Who Achieved Best Overall Disease Response of CR, PR or Stable Disease (SD) [Disease Control Rate (DCR)] | 78.9 (68.1 to 87.5) | 70.4 (59.2 to 80.0) |
The EQ-5D is a quality-of-life instrument which allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a scale from 1 to 3 (no problem, some problems, and extreme problems, respectively). These combinations of attributes were converted into a weighted Health State Index score according to a United Kingdom population-based algorithm; the possible values for the Health State Index score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).
| Units on a Scale | Ramucirumab + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Cycle 1 (n = 69, 77) | -0.024 ± 0.1928 | -0.007 ± 0.1918 |
| Cycle 2 (n = 62, 66) | -0.021 ± 0.2190 | 0.006 ± 0.1961 |
| Cycle 3 (n = 48, 53) | -0.010 ± 0.2324 | -0.005 ± 0.1891 |
| Cycle 4 (n = 40, 48) | 0.015 ± 0.1683 | -0.026 ± 0.1610 |
| Cycle 5 (n = 32, 40) | 0.000 ± 0.2280 | -0.012 ± 0.1433 |
| Cycle 6 (n = 28, 36) | 0.035 ± 0.1741 | -0.005 ± 0.1409 |
| Cycle 7 (n = 25 ,31) | 0.002 ± 0.1857 | -0.039 ± 0.1282 |
| Cycle 8 (n = 23, 30) | -0.053 ± 0.1750 | -0.071 ± 0.1800 |
| 30-Day Follow Up (n= 56, 70) | -0.102 ± 0.2209 | -0.132 ± 0.3344 |
The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant responses to each item were measured using a visual analog scale (VAS) from 0 (best outcome) to 100 (worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom-specific items in the LCSS. The Total LCSS was the mean of all 9 LCSS items. Maximum improvement in LCSS scores, ASBI, and Total LCSS score was the largest decrease from baseline for each variable, which was the smallest (most negative or smallest positive) non-missing value among all change from baseline values for each variable.
| Millimeter | Ramucirumab + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Loss of Appetite (n=73, 79) | -12.5 ± 26.23 | -16.2 ± 21.45 |
| Fatigue (n=73, 80) | -4.9 ± 25.38 | -7.8 ± 23.59 |
| Cough (n=73, 80) | -4.4 ± 23.10 | -18.3 ± 23.83 |
| Dyspnea (n=73, 80) | -4.7 ± 23.09 | -8.7 ± 20.16 |
| Hemoptysis (n=73, 80) | -1.2 ± 12.83 | -3.7 ± 17.25 |
| Pain (n=73, 80) | -9.6 ± 23.66 | -9.0 ± 21.52 |
| Overall Symptoms (n=73, 80) | -7.1 ± 26.10 | -11.5 ± 19.83 |
| Interference with Activity Level (n=73, 80) | -8.4 ± 25.84 | -11.9 ± 21.98 |
| Quality of Life (n=73, 80) | -11.7 ± 28.06 | -12.7 ± 21.06 |
| ASBI (n=73, 79) | -2.82 ± 14.93 | -6.93 ± 12.06 |
| Total LCSS (n=73, 79) | -3.20 ± 15.64 | -7.13 ± 11.74 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ramucirumab + Docetaxel | — | 30/94 (31.9%) | 94/94 (100%) |
| Placebo + Docetaxel | — | 31/98 (31.6%) | 98/98 (100%) |
| Event | Ramucirumab + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 8/94 | 6/98 |
| Decreased appetiteMetabolism and nutrition disorders | 4/94 | 1/98 |
| Metastases to meningesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/94 | 4/98 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 3/94 | 3/98 |
| Lung infectionInfections and infestations | 1/94 | 3/98 |
| General physical health deteriorationGeneral disorders | 2/94 | 0/98 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 2/94 | 2/98 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/94 | 1/98 |
| SplenomegalyBlood and lymphatic system disorders | 1/94 | 0/98 |
| Anorectal disorderGastrointestinal disorders | 1/94 | 0/98 |
| Event | Ramucirumab + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Neutrophil count decreasedInvestigations | 73/94 | 69/98 |
| White blood cell count decreasedInvestigations | 73/94 | 68/98 |
| AlopeciaSkin and subcutaneous tissue disorders | 63/94 | 61/98 |
| Decreased appetiteMetabolism and nutrition disorders | 54/94 | 51/98 |
| StomatitisGastrointestinal disorders | 50/94 | 31/98 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 46/94 | 18/98 |
| MalaiseGeneral disorders | 43/94 | 47/98 |
| AnaemiaBlood and lymphatic system disorders | 37/94 | 41/98 |
| NauseaGastrointestinal disorders | 34/94 | 39/98 |
| Oedema peripheralGeneral disorders | 34/94 | 28/98 |
All randomized participants who had received at least one dose of study drug.
| Age, Continuous(Years) | Ramucirumab + Docetaxel | Placebo + Docetaxel | Total |
|---|---|---|---|
| Median | 63.9 (29 to 78) | 64.1 (27 to 79) | 64 (27 to 79) |
| Sex: Female, Male(Participants) | Ramucirumab + Docetaxel | Placebo + Docetaxel | Total |
|---|---|---|---|
| Female | 28 | 27 | 55 |
| Male | 66 | 71 | 137 |
| Race (NIH/OMB)(Participants) | Ramucirumab + Docetaxel | Placebo + Docetaxel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 94 | 98 | 192 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Ramucirumab + Docetaxel | Placebo + Docetaxel | Total |
|---|---|---|---|
| Japan | 94 | 98 | 192 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Dec 2012, a primary completion of Dec 2014 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab
Carcinoma, Non-Small-Cell Lung →